[GENOMIC PROFILING IN LUMINAL BREAST CANCER]

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Breast cancer is not a single disease but a spectrum of distinct subtypes.
• Estrogen receptor (ER) positive breast cancer exhibits significant heterogeneity, with Luminal A and Luminal B subtypes showing different biological behaviors and prognoses.
• Genomic profiling using microarrays has been pivotal in understanding this heterogeneity.

Purpose of the Study:

• To review the clinical and scientific basis of commercially available genomic assays for breast cancer.
• To elucidate the differences between these assays and their current clinical applications.
• To provide a comprehensive overview of genomic testing in breast cancer management.

Main Methods:

• Review of scientific literature and clinical data on genomic profiling in breast cancer.
• Analysis of five commercial genomic assays: Oncotype Dx, Mamaprint, Prosigna, Endopredict, and Breast Cancer Index.
• Summarization of the clinical utility and performance of these assays.

Main Results:

• Genomic profiling has identified distinct subtypes of breast cancer, impacting prognosis and treatment response.
• Five commercial assays are currently used to assess recurrence risk and chemotherapy benefit.
• These tests assist oncologists and patients in making informed decisions about omitting or pursuing chemotherapy.

Conclusions:

• Genomic tests are essential tools in personalized breast cancer treatment.
• Understanding the differences between available genomic assays is crucial for optimal clinical application.
• These assays empower clinicians to tailor treatment strategies based on individual tumor biology, improving patient outcomes.